This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

About Oxbryta®Clinical Trial DataSafety ProfileDosing Experience with Oxbryta Supporting ResourcesSupporting ResourcesContact UsVideosDownloadable resources

Click here for Oxbryta®▼ (voxelotor) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

About Oxbryta®Indication

Oxbryta® (voxelotor) is indicated for the treatment of haemolytic anaemia due to sickle cell disease (SCD) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.1

SCD is associated with substantial disease burden
  • Sickle cell disease affects an estimated 15,000 people in the UK2
  • Sickle cell disease is characterised by progressive and cumulative organ damage, and a shortened life expectancy (estimated median 67 years in the UK)3–6
Haemoglobin S (HbS) polymerisation is the molecular basis of SCD
  • HbS polymerisation causes red blood cell (RBC) sickling and haemolytic anaemia;4,7–9 released components of haemolysed RBCs contribute to vasomotor dysfunction and vasculopathy, among other events8
  • Haemolytic anaemia – along with vasculopathy and other features of the pathophysiology – contributes to sickle cell disease complications3,8

Patient Experience

Watch the video below to listen to a patient with Sickle Cell Disease talk about their experience of living with the disease & Oxbryta ® treatment. 

Click to viewLoading

Oxbryta® targets HbS polymerisation, which could reduce morbidity and mortality in sickle cell disease

  • By inhibiting HbS polymerisation, Oxbryta® offers the potential to reduce haemolytic anaemia and its downstream effects1,7

Click to watch a video demonstrating the mechanism of action of Oxbryta® 

HbS, haemoglobin S; RBC, red blood cell; RVH, right ventricular hypertrophy; VOC, vaso-occlusive crisis.

Dosing and administration

What you need to know about Oxbryta® in clinical practice

DosingLoading
Clinical trial data

Discover the efficacy and safety profile of Oxbryta® from the HOPE clinical trial

DataLoading
KickerReferences:1. Oxbryta® (voxelotor) Summary of Product Characteristics.
2. Sickle Cell Society. About sickle cell. Available at https://www.sicklecellsociety.org/about-sickle-cell/. Accessed July 2023.
3. Ataga KI, et al. PLoS One. 2020;15(4):e0229959.
4. Kato GJ, et al. Nat Rev Dis Primers. 2018;4:18010.
5. Oguanobi NI, et al. ISRN Hematol. 2012;2012:768718.
6. NICE. Clinical knowledge summary: Sickle cell disease. Available at https://cks.nice.org.uk/topics/sickle-cell-disease/background-information/prognosis/. Accessed July 2023
7. Vichinsky E, et al. N Engl J Med. 2019;381(6):509–519.
8. Kato GJ, et al. J Clin Invest. 2017;127(3):750–760.
9. AlDallal SM, et al. Cureus. 2020;12(2):e7105.
PP-LTV-GBR-0212 January 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​